Cardiology

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The label expansion for semaglutide, based on the SELECT trial, includes data showing reduced risk of CV death of 15% and of death from any cause of 19%.

Few participants with dyslipidemia received lipid-lowering medications despite high prevalence, reported authors of the Strong Family Heart Study.

Authors: Exclusion of people with CKD from CV medication trials has left significant gaps in understanding the effectiveness of these drugs in a highly vulnerable population.

Your daily dose of the clinical news you may have missed.

Patients who had microplastics and nanoplastics in their carotid plaque were at more than a fourfold risk for MI, stroke, or death compared to those who did not, according to a new study.

Your daily dose of the clinical news you may have missed.

Topline KARDIA-2 findings showed zilebesiran led to clinically and statistically significant reductions in SBP on top of either a diuretic, CCB, or ARB.

Your daily dose of the clinical news you may have missed.

Semaglutide 1.0 mg was superior to placebo across the FLOW trial's 5-part primary endpoint with both CKD and CVD components contributing to risk reduction, said Novo Nordisk.

The 3-year risk of rapid progression from CKD stage G3 was 15% in a large Danish population. Study authors identified accessible key risk factors to aid early detection.

Women with migraine and persistent VMS faced double the risk of CVD and triple the risk of stroke, reported researchers.

The risk for cardiovascular outcomes increased with more frequent reported cannabis use per month, according to results from a large national study.

Analysis of heart registry data for SELECT trial-eligible adults (obesity, first MI, no diabetes) found an NNT of 49 and 5-year MACE incidence of 10.7%.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Older adults with normal BP levels in China were approximately 40% less likely to develop HTN when using a salt substitute for 2 years, according to a new study.

Your daily dose of the clinical news you may have missed.

Women with adverse pregnancy outcomes face a significantly higher risk of cardiovascular disease and stroke later in life, according to the statement.

Your daily dose of the clinical news you may have missed.

Women aged 40 to 65 years who had persistent insomnia and poor sleep duration were at a 75% greater risk for incident CVD over 2 decades of follow up.

Acute, preventable diabetes complications days fell by 8.4% among participants enrolled in a preventive drug list benefit and by even more among low-income subscribers.

Your daily dose of the clinical news you may have missed.

Anticoagulation and antiplatelet therapy appeared equally effective in reducing risk of recurrent stroke following cryptogenic stroke in persons with evidence of atrial cardiopathy.

Amgen's investigational maridebart cafraglutide in a phase 1 trial led to durable weight reduction following less frequent and lower doses, the company said.

Mean placebo-adjusted SBP change from baseline at 36 weeks was 8.6 mm Hg in adults with obesity, according to authors of the SURMOUNT-1 ABPM substudy.

In apixaban-treated participants, risk of stroke or systemic embolism was reduced by 37%; the risk of disability or fatal stroke declined by 49%, but with noted bleeding risk.

Low-dose calcium supplementation with 500 mg/day may be as protective against poor pregnancy outcomes as the WHO-recommended dose of 1500 mg/day.

Heart disease has been the primary cause of death in the US for the last century, and yet 51% of adults do not recognize the fact.